

# Oklahoma Health Care Authority

Drug Utilization Review Board

(DUR Board)

Meeting – July 10, 2024 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:** *The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.*

## **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

### **1. Call to Order**

A. Roll Call – Dr. Wilcox

### **DUR Board Members:**

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Bret Haymore –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person
Dr. Cindy West –	participating in person

### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://oklahoma.zoom.us/webinar/register/WN\\_94lCoSe9Ty2msgsLMqg2Ww](https://oklahoma.zoom.us/webinar/register/WN_94lCoSe9Ty2msgsLMqg2Ww)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 958 2294 2095

Passcode: 65079339

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. June 12, 2024 DUR Board Meeting Minutes
- B. June 12, 2024 DUR Board Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Metts, Dr. Travers Dr. Muchmore, Chairman:

### **4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence (CMA) Program Update – See Appendix B**

- A. Pharmacy Help Desk Activity for June 2024
- B. Medication Coverage Activity for June 2024
- C. CMA Program Update

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

### **5. Action Item – Vote to Prior Authorize Rezdifra™ (Resmetirom) – See Appendix C**

- A. Market News and Updates
- B. Rezdifra™ (Resmetirom) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Risvan® (Risperidone Extended-Release Injection) and Update the Approval Criteria for the Atypical Antipsychotic Medications – See Appendix D**

- A. Market News and Updates
- B. Risvan® (Risperidone Extended-Release Injection) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Baclofen 15mg Tablet, Chlorzoxazone 250mg Tablet, Clindacin® ETZ Kit (Clindamycin 1% Swabs and Cleanser), Combogesic® IV [Acetaminophen/Ibuprofen Intravenous (IV)], Elyxyb™ (Celecoxib Oral Solution), Ingrezza® Sprinkle (Valbenazine), Lodoco® (Colchicine), Millipred™ (Prednisolone 5mg Tablet), Motpoly XR™ [Lacosamide Extended-Release (ER) Capsule], Neo-Synalar® (Neomycin/Fluocinolone Cream), Ozobax® DS [Baclofen Double Strength (DS) 10mg/5mL Oral Solution], PoKonza™ (Potassium Chloride 10mEq Packet for Oral Solution), Suflave™ [Polyethylene Glycol (PEG)-3350/Sodium Sulfate/Potassium Chloride/Magnesium Sulfate/Sodium Chloride], and Valsartan Oral Solution and Update the Approval Criteria for the Various Special Formulations – See Appendix E**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Qalsody™ (Tofersen) and Rilutek® (Riluzole) and Update the Approval Criteria for the Amyotrophic Lateral Sclerosis (ALS) Medications – See Appendix F**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**9. Action Item – Vote to Prior Authorize Liqrev® (Sildenafil Oral Suspension), Opsynvi® (Macitentan/Tadalafil), and Winrevair™ (Sotatercept-csrk) and Update the Approval Criteria for the Pulmonary Arterial Hypertension (PAH) Medications – See Appendix G**

- A. Market News and Updates
- B. Product Summaries
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

**10. Action Item – Vote to Prior Authorize Akeega™ (Niraparib/Abiraterone Acetate) and Update the Approval Criteria for the Genitourinary and Gynecologic Cancer Medications – See Appendix H**

- A. Market News and Updates
- B. Akeega™ (Niraparib/Abiraterone Acetate) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**11. Action Item – Annual Review of Testosterone Products – See Appendix I**

- A. Current Prior Authorization Criteria
- B. Utilization of Testosterone Products
- C. Prior Authorization of Testosterone Products
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Testosterone Products

Items to be presented by Dr. Sinko, Dr. Muchmore, Chairman:

**12. Annual Review of Colorectal Cancer Medications and 30-Day Notice to Prior Authorize Avzivi® (Bevacizumab-tjnj) and Fruzaqla® (Fruquintinib) – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of Colorectal Cancer Medications
- C. Prior Authorization of Colorectal Cancer Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Colorectal Cancer Medications

Items to be presented by Dr. O'Halloran Dr. Muchmore, Chairman:

**13. 30-Day Notice to Prior Authorize Wegovy® (Semaglutide) – See Appendix K**

- A. Introduction
- B. Market News and Updates
- C. Wegovy® (Semaglutide) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**14. Annual Review of Epidermolysis Bullosa (EB) Medications and 30-Day Notice to Prior Authorize Filsuvez® (Birch Triterpenes Topical Gel) – See Appendix L**

- A. Current Prior Authorization Criteria
- B. Utilization of EB Medications
- C. Prior Authorization of EB Medications
- D. Market News and Updates
- E. Filsuvez® (Birch Triterpenes Topical Gel) Product Summary

- F. College of Pharmacy Recommendations
- G. Utilization Details of EB Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**15. Annual Review of Alzheimer's Disease Medications and 30-Day Notice to Prior Authorize Kisunla™ (Donanemab-azbt) – See Appendix M**

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer's Disease Medications
- C. Prior Authorization of Alzheimer's Disease Medications
- D. Market News and Updates
- E. Kisunla™ (Donanemab-azbt) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Alzheimer's Disease Medications

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

**16. 30-Day Notice to Prior Authorize Defencath® (Taurolidine/Heparin Catheter Lock System) – See Appendix N**

- A. Introduction
- B. Market News and Updates
- C. Defencath® (Taurolidine/Heparin Catheter Lock System) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Metts, Dr. Muchmore, Chairman:

**17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**18. Future Business\* (Upcoming Product and Class Reviews)**

***No live DUR Board meeting scheduled for August 2024. August 2024 will be a packet-only meeting.***

- A. Corticosteroid Special Formulations
- B. Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications
- C. Topical Corticosteroids
- D. Various Systemic Antibiotics

\*Future product and class reviews subject to change.

**19. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.